文献速递肿瘤 PET/CT核素与放射性配体治疗

探索目前可用的成纤维细胞活化蛋白靶向分子在肾上腺皮质癌中的应用:导航诊疗一体化路径

Exploring currently available fibroblast activation protein targeting molecules in adrenocortical carcinoma: Navigating theranostic pathways.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-03-22

本研究纳入30例经组织病理学证实的局限性或转移性肾上腺皮质癌患者,分别接受FDG PET和四种FAPi衍生物PET显像。整体分析显示FAPi与FDG的SULpeak、SULavg及TBR均无显著差异,容积分析中TLF与TLG也无显著差异。结论认为现有FAP抑制剂分子在描绘疾病播散方面与FDG PET相当,并可能作为肾上腺皮质癌管理的潜在诊疗一体化靶点。

要点

  • FAPi与FDG PET在整体分析中SULpeak、SULavg及TBR均无显著差异。
  • DATA.FAPi和FAPi46在转移性疾病中与FDG扫描结果100%一致。
  • SA.FAPi因检测到额外骨骼病灶而表现出33%的不一致,C4.FAPi因漏诊一个肝脏病灶而表现出10%的不一致。

核心结论

  • 所有现有FAP抑制剂分子在描绘疾病播散方面与FDG PET相当,并可能作为肾上腺皮质癌管理的潜在诊疗一体化靶点。

研究设计与样本

  • 研究纳入30例经组织病理学证实的局限性或转移性肾上腺皮质癌病例,均接受FDG和FAPi PET显像。
  • SA.FAPi组n=5,DATA.FAPi组n=5,C4.FAPi组n=5,FAPi46组n=15。
  • 通过勾画体部各器官感兴趣区计算标准化摄取值以进行生物分布分析。
  • 采用瘦体重校正的标准化摄取值、肿瘤与本底比值、FDG的总病灶糖酵解及FAPi的总病灶FAP表达进行病灶示踪摄取定量比较分析。

主要发现

  • 整体分析中,FAPi与FDG的平均SULpeak为4.3(8.0-1.7)vs 3.9(8.1-2.5),p=0.271;平均SULavg为2.2(4.3-1.2)vs 2.2(3.4-1.3),p=0.897;平均TBR为1.8(3.2-1.2)vs 1.9(2.7-1.2),p=0.696。
  • 容积分析中,队列的平均TLF与平均TLG为9.3(53.7-4.5)vs 11.8(33.0-4.3),p=0.107。
  • 亚组分析显示两种放射性示踪剂在检测所有原发病灶、淋巴结病灶及肺和腹膜远处转移方面结果完全一致,而在肝脏病灶(22%)和骨骼病灶(33%)方面结果不一致。
  • 在转移性疾病病灶检测中,DATA.FAPi和FAPi46与FDG扫描结果100%一致;SA.FAPi因检测到一个额外骨骼病灶而表现出33%不一致;C4.FAPi因漏诊一个FDG识别的肝脏病灶而表现出10%不一致。
  • 三种68Ga-FAP衍生物(SA.FAPi、DATA.FAPi和C4.FAPi)生物分布相似,在唾液腺、甲状腺、肝脏、胰腺、肌肉和肾脏中有摄取,在泪腺、眼外肌、口腔黏膜和子宫中摄取可变;FAPi46生理性表达见于唾液腺和肌肉,其他器官无摄取。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Cancer-associated fibroblasts (CAFs) expressing fibroblast activation protein (FAP) in the adrenocortical carcinoma (ACC) microenvironment may be used as potential therapeutic targets. This study investigated the diagnostic potential of four FAPi derivatives i.e. DOTA-FAPi-46 (FAPi46), DOTA.SA.FAPi (SA.FAPi), DATA5m.SA.FAPi (DATA.FAPi) and DATA5m.C4.FAPi (C4.FAPi) and compared with standard-of-care 18F-FDG (FDG) in ACC. METHODS: Thirty histopathological proven cases of localized or metastatic ACC were recruited for both FDG and FAPi PET (number of patients (n) = 5 for SA.FAPi, n = 5 for DATA.FAPi, n = 5 for C4.FAPi and n = 15 for FAPi46). For biodistribution, standardized uptake values (SUV's) were computed by delineating region-of-interest on various body organs. For comparative analysis in disease identification, lesion tracer uptake was quantified using standardized uptake values corrected for lean body mass (SUL), tumor-to-background ratio (TBR), total lesion glycolysis (TLG for FDG) and total lesion FAP expression (TLF for FAPi). RESULTS: In overall analysis, both FAPi and FDG PET exhibited comparable mean SULpeak [FAPi 4.3 (8.0-1.7) vs FDG 3.9 (8.1-2.5), p-0.271], mean SULavg [2.2 (4.3-1.2) vs 2.2 (3.4-1.3), p-0.897] and mean TBR [1.8 (3.2-1.2) vs 1.9 (2.7-1.2), p-0.696]. In volumetric analysis, comparable mean TLF and mean TLG was noted for the cohort [9.3 (53.7-4.5) vs 11.8 (33.0-4.3), p-0.107]. Sub-categorical analysis demonstrated complete concordant findings for both radiotracers in detection of all primary lesions, nodal lesions and distant metastases in lung and peritoneum with discordant findings in liver (22%) and skeletal lesions (33%). For lesion detection, DATA.FAPi and FAPi46 showed 100% concordance with FDG scan findings in metastatic disease. SA.FAPi exhibited 33% discordance by detecting an additional skeletal lesion, while C4.FAPi had 10% discordance, missing one liver lesion identified by FDG. Three 68 Ga-FAP derivatives (SA.FAPi, DATA.FAPi, and C4.FAPi) exhibited similar biodistribution, with uptake in the salivary glands, thyroid, liver, pancreas, muscles, and kidneys, and variable uptake in the lacrimal glands, extra-ocular muscles, oral mucosa, and uterus. In contrast, FAPi46 physiological expression was noted in salivary glands and muscles, with no uptake in other organs. Pancreatic uptake was highest for SA.FAPi (SUVmean 11.8), DATA.FAPi (12.1), and C4.FAPi (10.8), while FAPi46 had the lowest (1.7). Conversely, FAPi46 exhibited the highest muscle uptake (SUVmean 4.3) compared to SA.FAPi (1.7), DATA.FAPi (1.4), and C4.FAPi (1.0). CONCLUSION: All the existing FAP inhibitor molecules were comparable to FDG PET for mapping disease spread and appeared as potential theranostic targets for the management of ACC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Chopra S, Shukla J, Purohit P, et al. Exploring currently available fibroblast activation protein targeting molecules in adrenocortical carcinoma: Navigating theranostic pathways. Eur J Nucl Med Mol Imaging. 2025. PMID: 40119895. doi:10.1007/s00259-025-07203-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。